Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by The Conventional Clopidogrel Treatment

Related Conditions

Often studied with 11 related conditions

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed with results

Key Signals

2 with results100% success

Data Visualizations

Phase Distribution

1Total
Not Applicable (1)

Trial Status

Completed2

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT06665919Not ApplicableCompleted

The Study of CYP2C19 Genotype-Guided Clopidogrel Treatment Models

NCT01499511Completed

Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study

Showing all 2 trials

Research Network

Common Treatments

  • The Conventional Clopidogrel Treatment1
  • Cyp2c19 Genotype Guided Antiplatelet Treatment Alternative To Clopidogrel1
  • Cyp2c19 Genotypeguided Clopidogrel Treatment1

Active Sponsors

  • Pfizer1
  • Imperial College London1
  • Vistamedi Ltd.1
  • Tbilisi State Medical University1

Top Investigators

Related Conditions

  • Clopidogrel Resistance1
  • Diabetes1
  • Bleeding1
  • Adverse Cardiac Events1
  • Coronary Artery Disease1

Activity Timeline